22:37 , May 30, 2019 |  BC Extra  |  Company News

May 30 Company Quick Takes: Unity in-licenses protein for cognitive decline, plus Astellas, Organovo, Iovance

Unity in-licenses UCSF protein for cognitive improvement  Unity Biotechnology Inc. (NASDAQ:UBX) licensed from the University of California San Francisco exclusive, worldwide rights to IP relating to KLA, including its use to reverse or prevent cognitive...
21:19 , May 17, 2019 |  BioCentury  |  Emerging Company Profile

89bio: standing out in the NASH crowd

89bio thinks it can differentiate itself from companies targeting NASH as an inflammatory and fibrotic disease by attacking it as a metabolic disorder and addressing its root cause with an FGF analog that could be...
18:48 , Mar 26, 2019 |  BC Extra  |  Financial News

NGM could get $975M valuation in NASDAQ IPO

After setting its NASDAQ IPO terms on Monday, NGM would be valued at $975 million if it prices the offering at the midpoint of its proposed range. The valuation includes a concurrent private placement of...
17:23 , Mar 22, 2019 |  BC Week In Review  |  Company News

Merck extends discovery partnership with NGM, drops obesity candidate

Merck & Co. said it will extend by two years its research collaboration with NGM and provide an additional $20 million in R&D funding. The pair initially partnered for five years in 2015 to discover...
21:33 , Jan 4, 2019 |  BC Week In Review  |  Company News

Merck licenses NASH, diabetes compound from NGM

Merck & Co. Inc. (NYSE:MRK) exercised an option to license exclusive, worldwide rights to MK-3655 (formerly NGM313) from NGM Biopharmaceuticals Inc. (South San Francisco, Calif.). MK-3655, a mAb agonist of the klotho β (KLB)/fibroblast growth...
02:27 , Nov 3, 2018 |  BioCentury  |  Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
02:10 , Oct 20, 2018 |  BioCentury  |  Product Development

CVOT damage in diabetes

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...
20:14 , Oct 5, 2018 |  BC Week In Review  |  Financial News

New IPO filings include NGM, Arog, Gamida

Three biotechs filed late Sept. 28 to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
12:22 , Oct 1, 2018 |  BC Extra  |  Financial News

New IPO filings include NGM, Arog, Gamida

Three more biotechs filed late Friday to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
17:25 , Jun 29, 2018 |  BC Week In Review  |  Company News

China's Everest gets rights to Novartis' FGFR4 inhibitor

C-Bridge-backed Everest Medicines Ltd. (Shanghai, China) gained an exclusive, worldwide license to FGF401 from Novartis AG (NYSE:NVS; SIX:NOVN). The deal marks the second in-licensing of a fibroblast growth factor (FGF) receptor 4 (FGFR4; CD334) inhibitor...